research use only

Ulipristal Acetate (CDB 2914) Estrogen/progestogen Receptor modulator

Cat.No.S3081

Ulipristal acetate (CDB-2914, HRP 2000, RU 44675) is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.
Ulipristal Acetate (CDB 2914) Estrogen/progestogen Receptor modulator Chemical Structure

Chemical Structure

Molecular Weight: 475.62

Jump to

Quality Control

Batch: Purity: 99.95%
99.95

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (174.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 14 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 475.62 Formula

C30H37NO4

Storage (From the date of receipt)
CAS No. 126784-99-4 Download SDF Storage of Stock Solutions

Synonyms HRP 2000, RU 44675 Smiles CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)OC(=O)C

Mechanism of Action

Targets/IC50/Ki
Progesterone receptor
In vitro
Ulipristal acetate (CDB 2914) has partial agonistic as well as antagonistic effects on the progesterone receptor. It also binds to the glucocorticoid receptor, but has no relevant affinity to the estrogen, androgen and mineralocorticoid receptors.
In vivo
Based on clinical trials, Ulipristal Acetate (CDB 2914) seems to be a reasonably tolerable and effective method of emergency contraception when used within 120 hours of intercourse. It is at least as effective as LNG when used within the first 72 hours after unprotected intercourse. However, this compound may be more effective than LNG when used between 72 to 120 hours after unprotected intercourse, extending the window of opportunity for emergency contraception.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349190 Completed
Infertility Female|Fibroid Uterus
ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO|Gedeon Richter Plc.
December 29 2017 --
NCT03118297 Completed
Contraception|Bleeding
Washington University School of Medicine
May 1 2017 Phase 3
NCT03156127 Withdrawn
Uterine Myoma
Boryung Pharmaceutical Co. Ltd
May 19 2017 Phase 1
NCT02859337 Completed
Obesity|Contraception
Oregon Health and Science University|National Institutes of Health (NIH)
May 30 2017 Phase 4
NCT02408770 Completed
Breast Cancer
Manchester University NHS Foundation Trust|University of Manchester
January 22 2016 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map